Conditions: Atrial Fibrillation
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 222
Healthy volunteers: no

Brief summary:
To assess the effect of two doses of Apixaban (2.5 mg BID and 5 mg BID) versus Warfarin on the composite endpoint of major and clinically relevant non-major bleeding during the treatment period.

Detailed description:

Arms:
arm 1: None arm 2: None arm 3: None

Interventions: intervention 1: Apixaban intervention 2: Apixaban intervention 3: Warfarin sodium
Intervention descriptions: intervention 1: Apixaban 5 mg tablet BID for 12 weeks intervention 2: Apixaban 2.5 mg tablet BID for 12 weeks intervention 3: At each visit, the subject to take appropriate Warfarin tablet (on investigator's order) once a day every morning for 12 weeks

Protocol document: